Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Jae-Woo | - |
dc.contributor.author | Park, Hae-Sim | - |
dc.contributor.author | Park, Choon-Sik | - |
dc.contributor.author | Cho, Sang-Heon | - |
dc.contributor.author | Choi, Inseon S. | - |
dc.contributor.author | Moon, Hee-Bom | - |
dc.contributor.author | Kwon, Soon Seog | - |
dc.contributor.author | Yoon, Ho Joo | - |
dc.contributor.author | Park, Jung Won | - |
dc.contributor.author | Lee, Jong-Myung | - |
dc.contributor.author | Choi, Dong-Chull | - |
dc.contributor.author | Choi, Byoung Whui | - |
dc.date.accessioned | 2021-09-10T05:45:34Z | - |
dc.date.available | 2021-09-10T05:45:34Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.issn | 2005-6648 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18741 | - |
dc.description.abstract | Background/Aims: Omalizumab is the first biologic known to be effective in patients with severe allergic asthma. Methods: This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 weeks in Korean patients with severe persistent allergic asthma. Results: Of the 44 patients, 31.8% were men and the mean age was 49.8 +/- 11.8 years. A score improvement of 0.5 points or more in the Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) was noted in 50.0% (22/44) of the patinets. In the improved group, the baseline total immunoglobulin E (IgE) level and the amount of omalizumab used were higher, and the day and night asthma symptoms were more severe, compared to those in the non-improved group. According to the Global Evaluation of Treatment Effectiveness, favorable outcomes were found in 78.6% of patients. The Korean asthma control test (p < 0.005) and forced expiratory volume in 1 second % predicted (FEV1%; p < 0.01) improved significantly in patients who received omalizumab treatment, compared to that at week o, and the total dose of rescue systemic corticosteroids significantly decreased (p < 0.05). The improved group on KAQLQ showed a significant improvement in FEV1% (p < 0.001). Conclusions: Omalizumab can be considered a biological treatment for Korean patients with severe allergic asthma. It is recommended to consider omalizumab as add-on therapy in patients with high baseline total IgE levels and severe asthma symptoms. | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한내과학회 | - |
dc.title | Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3904/kjim.2020.549 | - |
dc.identifier.scopusid | 2-s2.0-85111059133 | - |
dc.identifier.wosid | 000669004600001 | - |
dc.identifier.bibliographicCitation | The Korean Journal of Internal Medicine, v.36, no.4, pp 1001 - 1013 | - |
dc.citation.title | The Korean Journal of Internal Medicine | - |
dc.citation.volume | 36 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1001 | - |
dc.citation.endPage | 1013 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | ANTI-IGE ANTIBODY | - |
dc.subject.keywordPlus | BIOLOGICS | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordAuthor | Omalizumab | - |
dc.subject.keywordAuthor | Quality of life | - |
dc.subject.keywordAuthor | Republic of Korea | - |
dc.subject.keywordAuthor | Asthma | - |
dc.subject.keywordAuthor | Prospective studies | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.